Effects of different immunosuppressive regimens on regulatory T-cells in noninflamed colon of liver transplant recipients

Inflammatory Bowel Diseases

Volumn 13, Issue 6, 2007, Pages 703-709

  Verdonk, Robert C ^a   Haagsma, E B ^a   Jonker, M R ^a   Bok, L I H ^a   Zandvoort, J H ^a   Kleibeuker, J H ^a   Faber, K N ^a   Dijkstra, G ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Foxp3; Immunosuppression; Inflammatory bowel disease; Liver transplantation; Regulatory T cells; TGF

Indexed keywords

AZATHIOPRINE; CD3 ANTIGEN; CYCLOSPORIN; INTERLEUKIN 10; MESSENGER RNA; PREDNISOLONE; SMAD3 PROTEIN; SMAD7 PROTEIN; TACROLIMUS; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COLON BIOPSY; COLON MUCOSA; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GRAFT RECIPIENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REGULATORY T LYMPHOCYTE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; AGED; ANTIGENS, CD3; AUTOIMMUNITY; BIOPSY; COLON; DISEASE PROGRESSION; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION; GRAFT REJECTION; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-10; INTESTINAL MUCOSA; LIVER DISEASES; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; SMAD3 PROTEIN; SMAD7 PROTEIN; T-LYMPHOCYTES, REGULATORY; TRANSFORMING GROWTH FACTOR BETA;

EID: 34250311983     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20087     Document Type: Article

References (47)

1. Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002;347: 417-429.
2. Chatila TA. Role of regulatory T cells in human diseases. J Allergy Clin Immunol. 2005;116:949-959.
3. O'Garra A, Vieira P. Regulatory T cells and mechanisms of immune system control. Nat Med. 2004;10:801-805.
4. Scheffold A, Huhn J, Hofer T. Regulation of CD4+CD25+ regulatory T cell activity: it takes (IL-)two to tango. Eur J Immunol. 2005;35:1336-1341.
5. Yagi H, Nomura T, Nakamura K, et al. Crucial role of FOXP3 in the development and function of human CD25+CD4+ regulatory T cells. Int Immunol. 2004;16:1643-1656.
6. Coombes JL, Robinson NJ, Maloy KJ, Uhlig HH, Powrie F. Regulatory T cells and intestinal homeostasis. Immunol Rev. 2005;204:184-194.
7. Maul J, Loddenkemper C, Mundt P, et al. Peripheral and intestinal regulatory CD4+ CD25(high) T cells in inflammatory bowel disease. Gastroenterology. 2005;128:1868-1878.
8. Takahashi M, Nakamura K, Honda K, et al. An inverse correlation of human peripheral blood regulatory T cell frequency with the disease activity of ulcerative colitis. Dig Dis Sci. 2006;51:677-686.
9. Baan CC, van der Mast BJ, Klepper M, et al. Differential effect of calcineurin inhibitors, anti-CD25 antibodies and rapamycin on the induction of FOXP3 in human T cells. Transplantation. 2005;80:110-117.
10. Demirkiran A, Kok A, Kwekkeboom J, Metselaar HJ, Tilanus HW, van der Laan LJ. Decrease of CD4+CD25+ T cells in peripheral blood after liver transplantation: association with immunosuppression. Transplant Proc. 2005;37:1194-1196.
11. Shibutani S, Inoue F, Aramaki O, et al. Effects of immunosuppressants on induction of regulatory cells after intratracheal delivery of alloantigen. Transplantation. 2005;79:904-913.
12. Slebos DJ, Kauffman HF, Koeter GH, Verschuuren EA, Bij W, Postma DS. Airway cellular response to two different immunosuppressive regimens in lung transplant recipients. Clin Transplant. 2005;19:243-249.
13. van der Mast BJ, Rischen-Vos J, de Kuiper P, Vaessen LM, van Besouw NM, Weimar W. Calcineurin inhibitor withdrawal in stable kidney transplant patients decreases the donor-specific cytotoxic T lymphocyte precursor frequency. Transplantation. 2005;80:1220-1225.
14. Zhang H, Chua KS, Guimond M, et al. Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatory T cells. Nat Med. 2005;11:1238-1243.
15. Haagsma EB, Van Den Berg AP, Kleibeuker JH, Slooff MJ, Dijkstra G. Inflammatory bowel disease after fiver transplantation: the effect of different immunosuppressive regimens. Aliment Pharmacol Ther. 2003;18:33-44.
16. Verdonk RC, Dijkstra G, Haagsma EB, et al. Inflammatory bowel disease after liver transplantation: risk factors for recurrence and de novo disease. Am J Transplant. 2006;6:1422-1429.
17. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25:402-408.
18. O'Neil DA, Porter EM, Elewaut D, et al. Expression and regulation of the human beta-defensins hBD-1 and hBD-2 in intestinal epithelium. J Immunol. 1999;163:6718-6724.
19. Wehkamp J, Fellermann K, Herrlinger KR, et al. Human beta-defensin 2 but not beta-defensin 1 is expressed preferentially in colonic mucosa of inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2002;14:745-752.
20. Avery A, Paraskeva C, Hall P, Flanders KC, Sporn M, Moorghen M. TGF-beta expression in the human colon: differential immunostaining along crypt epithelium. Br J Cancer. 1993;68:137-139.
21. Babyatsky MW, Rossiter G, Podolsky DK. Expression of transforming growth factors alpha and beta in colonic mucosa in inflammatory bowel disease. Gastroenterology. 1996;110:975-984.
22. Xian CJ, Xu X, Mardell CE, et al. Site-specific changes in transforming growth factor-alpha and -beta1 expression in colonic mucosa of adolescents with inflammatory bowel disease. Scand J Gastroenterol. 1999; 34:591-600.
23. Vieira PL, Christensen JR, Minaee S, et al. IL-10-secreting regulatory T cells do not express Foxp3 but have comparable regulatory function to naturally occurring CD4+CD25+ regulatory T cells. J Immunol. 2004; 172:5986-5993.
24. Monteleone G, Kumberova A, Croft NM, McKenzie C, Steer HW, MacDonald TT. Blocking Smad7 restores TGF-beta1 signaling in chronic inflammatory bowel disease. J Clin Invest. 2001;108:601-609.
25. Fiocchi C. TGF-beta/Smad signaling defects in inflammatory bowel disease: mechanisms and possible novel therapies for chronic inflammation. J Clin Invest. 2001;108:523-526.
26. Coenen JJ, Koenen HJ, van Rijssen E, Hilbrands LB, Joosten I. Rapamycin, and not cyclosporin A, preserves the highly suppressive CD27+ subset of human CD4+CD25+ regulatory T cells. Blood. 2006;107:1018-1023.
27. Baan CC, van Riemsdijk-van Overbeeke IC, Balk AH, et al. Conversion from cyclosporin A to tacrolimus is safe and decreases blood pressure, cholesterol levels and TGF-beta 1 type I receptor expression. Clin Transplant. 2001;15:276-283.
28. Citterio F, Pozzetto U, Romagnoli J, et al. Plasma levels of transforming growth factor-beta1 in renal transplant recipients receiving different immunosuppressive regimens. Transplant Proc. 2004;36:698-699.
29. Esposito C, Foschi A, Parrilla B, et al. Effect of calcineurin inhibitors on extracellular matrix turnover in isolated human glomeruli. Transplant Proc. 2004;36:695-697.
30. Hughes JR, Hughes VF, Trull AK, Metcalfe SM. Blood levels of TGFbeta1 in liver transplant recipients receiving either tacrolimus or micro-emulsified cyclosporine. Transplantation. 1999;68:583-586.
31. Jain S, Mohamed MA, Sandford R, Furness PN, Nicholson ML, Talbot D. Sequential protocol biopsies from renal transplant recipients show an increasing expression of active TGF beta. Transpl Int. 2002;15:630-634.
32. Maluccio M, Sharma V, Lagman M, et al. Tacrolimus enhances transforming growth factor-beta1 expression and promotes tumor progression. Transplantation. 2003;76:597-602.
33. Mohamed MA, Robertson H, Booth TA, et al. Active TGF-beta1 expression in kidney transplantation: a comparative study of cyclosporin-A (CyA) and tacrolimus (FK506). Transpl Int. 2000;13(Suppl 1):S295-S298.
34. Shin GT, Khanna A, Ding R, et al. In vivo expression of transforming growth factor-beta1 in humans: stimulation by cyclosporine. Transplantation. 1998;65:313-318.
35. Zhang JG, Walmsley MW, Moy JV, et al. Differential effects of cyclosporin A and tacrolimus on the production of TGF-beta: implications for the development of obliterative bronchiolitis after lung transplantation. Transpl Int. 1998;11(Suppl 1):S325-S327.
36. Koenen HJ, Michielsen EC, Verstappen J, Fasse E, Joosten I. Superior T-cell suppression by rapamycin and FK506 over rapamycin and cyclosporine A because of abrogated cytotoxic T-lymphocyte induction, impaired memory responses, and persistent apoptosis. Transplantation. 2003;75:1581-1590.
37. Korb LC, Mirshahidi S, Ramyar K, Sadighi Akha AA, Sadegh-Nasseri S. Induction of T cell anergy by low numbers of agonist ligands. J Immunol. 1999;162:6401-6409.
38. Lenardo MJ. Interleukin-2 programs mouse alpha beta T lymphocytes for apoptosis. Nature. 1991;353:858-861.
39. Sandalova E, Wei CH, Masucci MG, Levitsky V. Regulation of expression of Bcl-2 protein family member Bim by T cell receptor triggering. Proc Natl Acad Sci USA. 2004;101:3011-3016.
40. Strauss G, Osen W, Debatin KM. Induction of apoptosis and modulation of activation and effector function in T cells by immunosuppressive drugs. Clin Exp Immunol. 2002;128:255-266.
41. Van Gool SW, de Boer M, Ceuppens JL. The combination of anti-B7 monoclonal antibody and cyclosporin A induces alloantigen-specific anergy during a primary mixed lymphocyte reaction. J Exp Med. 1994; 179:715-720.
42. Haagsma EB, Hagens VE, Schaapveld M, et al. Increased cancer risk after liver transplantation: a population-based study. J Hepatol. 2001;34:84-91.
43. Herrero JL Espana A, Quiroga J, et al. Nonmelanoma skin cancer after liver transplantation. Study of risk factors. Liver Transpl. 2005;11:1100-1106.
44. Silva MA, Jambulingam PS, Mirza DF. Colorectal cancer after orthotopic liver transplantation. Crit Rev Oncol Hematol. 2005;56:147-153.
45. Atassi T, Thuluvath PJ. Risk of colorectal adenoma in liver transplant recipients compared to immunocompetent control population undergoing routine screening colonoscopy. J Clin Gastroenterol. 2003;37:72-73.
46. Hojo M, Morimoto T, Maluccio M, et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature. 1999;397:530-534.
47. Majno P, Giostra E, Mentha G. Is there a customised immunosuppressive regimen for patients transplanted with hepatocellular carcinoma? J Hepatol. 2005;43:577-584.